- Home
- AKAN vs SCNI Comparison
AKAN vs SCNI Comparison
Compare AKAN & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKAN
- SCNI
- Stock Information
- Founded
- AKAN 2021
- SCNI 2003
- Country
- AKAN United Kingdom
- SCNI Israel
- Employees
- AKAN N/A
- SCNI N/A
- Industry
- AKAN Medicinal Chemicals and Botanical Products
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AKAN Health Care
- SCNI Health Care
- Exchange
- AKAN Nasdaq
- SCNI Nasdaq
- Market Cap
- AKAN 2.4M
- SCNI 2.8M
- IPO Year
- AKAN 2022
- SCNI N/A
- Fundamental
- Price
- AKAN $1.75
- SCNI $3.52
- Analyst Decision
- AKAN
- SCNI
- Analyst Count
- AKAN 0
- SCNI 0
- Target Price
- AKAN N/A
- SCNI N/A
- AVG Volume (30 Days)
- AKAN 120.7K
- SCNI 20.5K
- Earning Date
- AKAN 02-28-2025
- SCNI 11-22-2024
- Dividend Yield
- AKAN N/A
- SCNI N/A
- EPS Growth
- AKAN N/A
- SCNI N/A
- EPS
- AKAN N/A
- SCNI 8.20
- Revenue
- AKAN $2,508,317.00
- SCNI $452,000.00
- Revenue This Year
- AKAN N/A
- SCNI N/A
- Revenue Next Year
- AKAN N/A
- SCNI N/A
- P/E Ratio
- AKAN N/A
- SCNI $0.43
- Revenue Growth
- AKAN N/A
- SCNI N/A
- 52 Week Low
- AKAN $1.22
- SCNI $2.23
- 52 Week High
- AKAN $47.52
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- AKAN 56.48
- SCNI 52.91
- Support Level
- AKAN $1.46
- SCNI $3.30
- Resistance Level
- AKAN $1.78
- SCNI $3.60
- Average True Range (ATR)
- AKAN 0.10
- SCNI 0.25
- MACD
- AKAN 0.00
- SCNI -0.01
- Stochastic Oscillator
- AKAN 65.91
- SCNI 44.05
About AKAN Akanda Corp.
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The Company has three reportable segments: Cultivation, Distribution, and Corporate. Cultivating activities comprise the cultivation segment made up of the medical cannabis cultivation operations at RPK/Holigen in Portugal, and medical cannabis cultivation activities. Distributing activities relate to the distribution of medical cannabis by Canmart Ltd in the United Kingdom. Corporate activities entail head office costs and other general corporate expenses related to the administration of the broader group.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.